Furthermore, the classification model and selected DML discriminate among anti-CCP3(−) Controls, At-Risk and Early RA participants, and thus could ultimately lead to predictive algorithms that identify individuals at high-risk for progression to RA. This evidence concerns the gene AGBL3 and rheumatoid arthritis.